08.21.24
Stratum Nutrition, a U.S. ingredient supplier, has entered into an exclusive distribution agreement with OraTicx, a Korean oral probiotic specialist. Stratum will be the sole distributor of OraTicx’s products, which include live strains of oraCMU (Weissela cibaria CMU) and oraCMS1 (Weissella cibaria CMS1), as well as the postbiotic form of oraCMU across North America.
OraTicx’s probiotic formulations are designed to support oral and overall health, with multiple clinical studies supporting oraCMU’s ability to benefit oral microbiome balance while promoting dental health and fresh breath. In a recent randomized, double-blind, placebo-controlled clinical trial, volunteers in the treatment group had significant improvements in breath scores and a reduced presence of compounds that produce bad breath.
The same benefit was also shown in two canine clinical trials, the company reported. OraCMS1 has demonstrated potential immune support benefits in addition to an impact on measures of oral health in human clinical trials, while the postbiotic version of oraCMU has been supported via an in vitro mechanism of action study.
“OraTicx's high-quality oral probiotics will further strengthen our portfolio of clinically proven ingredients,” said Micah Osborne, CEO of Stratum Nutrition. “We are pleased to offer more diverse and effective health solutions to North American consumers in both human and pet markets through this partnership."
“This exclusive distribution agreement with Stratum Nutrition is an important opportunity for us to introduce our innovative oral probiotics to North American consumers,” said Eun-Seop Yoon, CEO of OraTicx. “By combining the expertise of both companies, we will create new value in the North American health functional food market and grow into a global leading company that contributes to a healthy life.”
OraTicx’s probiotic formulations are designed to support oral and overall health, with multiple clinical studies supporting oraCMU’s ability to benefit oral microbiome balance while promoting dental health and fresh breath. In a recent randomized, double-blind, placebo-controlled clinical trial, volunteers in the treatment group had significant improvements in breath scores and a reduced presence of compounds that produce bad breath.
The same benefit was also shown in two canine clinical trials, the company reported. OraCMS1 has demonstrated potential immune support benefits in addition to an impact on measures of oral health in human clinical trials, while the postbiotic version of oraCMU has been supported via an in vitro mechanism of action study.
“OraTicx's high-quality oral probiotics will further strengthen our portfolio of clinically proven ingredients,” said Micah Osborne, CEO of Stratum Nutrition. “We are pleased to offer more diverse and effective health solutions to North American consumers in both human and pet markets through this partnership."
“This exclusive distribution agreement with Stratum Nutrition is an important opportunity for us to introduce our innovative oral probiotics to North American consumers,” said Eun-Seop Yoon, CEO of OraTicx. “By combining the expertise of both companies, we will create new value in the North American health functional food market and grow into a global leading company that contributes to a healthy life.”
